Extended Data Table 4 Neopeptide recognition landscape

From: A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer

  1. Description of the neopeptide recognition landscape. Individual tumor mutational burden (non-synonymous mutations), haplotypes and predicted peptides found immunogenic at two time points (pre- and post-ACT) are reported.
Back to article page